{"id":4393,"date":"2026-11-17T16:15:00","date_gmt":"2026-11-17T20:15:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4393"},"modified":"2026-11-18T21:45:33","modified_gmt":"2026-11-19T01:45:33","slug":"merck-ends-nemtabrutinib-program-after-phase-3-review","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4393","title":{"rendered":"Merck Ends Nemtabrutinib Program After Phase 3 Review"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Merck_Nemtabrutinib_Therapeutic_Indications-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4410\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Merck_Nemtabrutinib_Therapeutic_Indications-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Merck_Nemtabrutinib_Therapeutic_Indications-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Merck_Nemtabrutinib_Therapeutic_Indications-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Merck_Nemtabrutinib_Therapeutic_Indications-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Merck_Nemtabrutinib_Therapeutic_Indications.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Merck<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Phase 3 program discontinuation (previously missed 17 Nov release)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Reversible noncovalent BTK inhibitor<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Nemtabrutinib (MK-1026)<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>BTK<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>CLL, SLL and other hematologic cancers<\/p>\n<h4>Summary<\/h4>\n<p>Merck discontinued the full BELLWAVE nemtabrutinib program for CLL, SLL and other hematologic cancers after an external data monitoring committee judged that benefit may not outweigh risk in Phase 3 BELLWAVE-011. Merck reviewed the totality of data and also stopped Phase 3 BELLWAVE-008 and -010. No efficacy or safety numbers were released.<\/p>\n<p>The company announced the decision at 4:15 p.m. Eastern on November 17, after the prior Insilens delivery. BELLWAVE-011 is NCT06136559; -008 is NCT05624554 and -010 is NCT05947851. Investigators are being informed. Merck said analyses continue and results will be shared. This is a source-gap addition, not a November 18 event.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> a trial-specific adverse risk\u2013benefit balance could reflect toxicity, insufficient efficacy, or both; stopping the entire program signals that Merck saw limited prospect of a viable therapeutic index across studied settings.<\/p>\n<p><strong>Interpretation B:<\/strong> the -011 finding might be population-, comparator- or regimen-specific, while program-wide termination reflects portfolio judgment rather than class failure. Neither explanation can be resolved without event rates, endpoints, dose exposure and subgroup data. Nemtabrutinib is a reversible, noncovalent BTK inhibitor intended to retain activity against some resistance mutations. Other BTK inhibitors cannot be judged from this molecule\u2019s undisclosed data. Cross-trial comparison is particularly hazardous given line of therapy, combination partner and infection-risk differences.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>CLL and SLL are mature B-cell malignancies dependent in part on B-cell-receptor signaling. Nemtabrutinib, MK-1026, reversibly inhibits BTK, including some mutant forms, to suppress that signal; Merck acquired the molecule with ArQule.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Primary company release verifies discontinuation and monitoring-committee concern; exact event profile, efficacy and attribution are missing.<\/li>\n<li>Upgrade an asset-specific mechanistic reading if detailed trial reports isolate the causal safety or efficacy deficit.<\/li>\n<li>Downgrade broad BTK-class inference if other noncovalent agents retain favorable randomized benefit\u2013risk.<\/li>\n<li>Falsify any toxicity-specific theory if discontinuation proves driven primarily by inadequate efficacy.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>This is a major negative development for nemtabrutinib and its three Phase 3 paths, while the reason and implications for other BTK molecules remain uncertain.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 5 of 5. Signal Direction: negative. Confidence in Facts: High. Confidence in Interpretation: Moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck discontinued the full BELLWAVE nemtabrutinib program for CLL, SLL and other hematologic cancers after an external data monitoring committee judged that benefit may not outweigh risk in Phase 3 BELLWAVE-011. Merck reviewed the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4410,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[161,123,1534],"class_list":["post-4393","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-chronic-lymphocytic-leukemia","tag-merck","tag-nemtabrutinib"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4393","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4393"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4393\/revisions"}],"predecessor-version":[{"id":4419,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4393\/revisions\/4419"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4410"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4393"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4393"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4393"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}